Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer

Background We assessed the efficacy and safety of bevacizumab and S-1 chemotherapy for patients with previously treated advanced non-squamous non-small-cell lung cancer (NSCLC). Methods This was a prospective single-arm study, including patients with non-squamous NSCLC who had received at least one...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical oncology 2021-03, Vol.26 (3), p.507-514
Hauptverfasser:	Hasegawa, Tsukasa, Yanagitani, Noriko, Ohyanagi, Fumiyoshi, Kudo, Keita, Horiike, Atsushi, Tambo, Yuichi, Nishikawa, Shingo, Ariyasu, Ryo, Uchibori, Ken, Kitazono, Satoru, Nishio, Makoto
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antineoplastic Combined Chemotherapy Protocols - adverse effects Bevacizumab Bevacizumab - adverse effects Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Diarrhea Humans Hypertension Immunotherapy Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medicine Medicine & Public Health Monoclonal antibodies Mucositis Neoplasm Staging Non-small cell lung carcinoma Oncology Oral administration Original Article Platinum Prospective Studies Proteinuria Safety Small cell lung carcinoma Surgical Oncology Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!